Good Sam Club Open Roads Forum: Around the Campfire: 2019–20 CORONAVIRUS PANDEMIC POSTINGS
Open Roads Forum Already a member? Login here.   If not, Register Today!  |  Help

Newest  |  Active  |  Popular  |  RVing FAQ Forum Rules  |  Forum Posting Help and Support  |  Contact  

Search:   Advanced Search

Search only in Around the Campfire

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–20 CORONAVIRUS PANDEMIC POSTINGS

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 116  
Prev
RambleOnNW

Pacific Northwest

Senior Member

Joined: 08/06/2010

View Profile



Good Sam RV Club Member


Posted: 04/12/21 04:40pm Link  |  Quote  |  Print  |  Notify Moderator

Saw this website posted on the news. A developer has put up a free website as a public service that collects all the available pharmacy C19 appointments by state and updates every minute. Nice user interface.

https://www.vaccinespotter.org/

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 04/14/21 11:20am Link  |  Quote  |  Print  |  Notify Moderator

Moderna’s mRNA vaccine was designed to produce the protein sequence that matches the sequence of the spike protein in the original variant. A preprint was posted on a study by Moderna (with Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health) where they have developed an mRNA vaccine that was designed to match the protein sequence of the spike protein in the South African variant.

They tested this new vaccine as a booster in mice already vaccinated with their first vaccine and they tested this new vaccine as a mixture with their original vaccine in mice that had never been vaccinated. Both vaccine tests (booster or new bi-valent vaccine) lead to strong antibody production in mice.

The booster vaccine increased the antibodies against the original variant and added antibodies against the South African variant. The bivalent vaccine elicited antibodies against the original and the South African variants.

Antibodies against the original variant provide variable cross reactivity to the other variants with the least cross reactivity to the South African variant. Antibodies against South African variant are expected to provide variable cross reactivity to the other variants. Having antibodies against both variants is expected to provide more protection to all current variants and potential new variants than having antibodies against just the original variant.

This study is an early step towards clinical trials of a booster vaccine and a new vaccine that provides better protection against the evolving virus.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439482

* This post was last edited 04/14/21 12:33pm by BCSnob *   View edit history

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 04/16/21 01:59pm Link  |  Quote  |  Print  |  Notify Moderator

Here is a review of a recent preprint on the rates of blood clots in the general population, those infected by COVID-19, infected with influenza, or vaccinated for COVID-19. The rates of blood clots were higher in those who were infected with Covid-19 (39/million) than those receiving either mRNA vaccine (4.1/million). In the USA there were 8 reported cases of blood clots after receiving the J&J vaccine out of the 7.4 million vaccinations with J&J (1.1/million).

Quote:

expert reaction to preprint looking at incidence of rare cerebral venous thrombosis (CVT) following COVID-19 infection compared to incidence after vaccination or influenza
science media centre > roundups for journalists >


The study was able to conclude, however, that the risk of CVT is increased, compared to the general population, in both people who have Covid-19 disease, and in people receiving the vaccines in the study. It found the following rates of disease:

Background rate of CVT: 0.41 per million people over any two-week period.

Rate of CVT following diagnosis of Covid-19: 39.0 per million people (95% CI, 25.2–60.2).

Rate of CVT following diagnosis of influenza: 0.0 per million people (95% CI 0.0–22.2).

Rate of CVT after receiving BNT162b2 or mRNA-1273 vaccine: 4.1 per million people (95% CI, 1.1–14.9)

Rate of PVT following Covid-19 disease: 436.4 per million people (95% CI, 382.9-497.4).

Rate of PVT following influenza: 98.4 per million people (95% CI, 61.4-157.6) after influenza.

Rate of PVT following mRNA vaccination: 44.9 per million people (95% CI, 29.7-68.0).


Btw the use of oral contraceptives increases the risk of CVT to about the risk of getting one of the Covid-19 vaccines.

Hormonal Contraceptives and Cerebral Ven........k: A Systematic Review and Meta-Analysis

* This post was last edited 04/16/21 03:20pm by BCSnob *   View edit history

rommroma557

USA

New Member

Joined: 03/16/2021

View Profile


Offline
Posted: 04/30/21 08:43am Link  |  Quote  |  Print  |  Notify Moderator

----------
Please post personal experiences with vaccines here:

Personal Covid Experiences

This site is for latest technical information and updates. Thanks.
(Mod)

* This post was edited 04/30/21 09:09am by an administrator/moderator *

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 116  
Prev

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–20 CORONAVIRUS PANDEMIC POSTINGS
Search:   Advanced Search

Search only in Around the Campfire


New posts No new posts
Closed, new posts Closed, no new posts
Moved, new posts Moved, no new posts

Adjust text size:




© 2021 CWI, Inc. © 2021 Good Sam Enterprises, LLC. All Rights Reserved.